Indole-3-Carbinol (I3C)
The parent compound that becomes DIM in the stomach. Choosing between the two is not just a branding question — the conversion is messy.
Indole-3-Carbinol (I3C) quick facts
| Suggested dose | 200–400 mg daily with food. |
| How often | daily |
| Who it's for | Estrogen metabolism support. Most people are better served by DIM. |
DIM is generally preferred precisely because it skips the variable conversion. I3C has more human trial data historically, including in cervical dysplasia, so it is not simply inferior. Same CYP induction caution. If stomach acid is low, from age or a PPI, conversion will be worse and DIM is clearly the better choice.
How Indole-3-Carbinol (I3C) actually works
The precursor from cruciferous vegetables that condenses into DIM in stomach acid. That conversion is the problem: it is variable, incomplete, and produces other condensation products besides DIM — some of which have their own activity, not all of it desirable.
Where to get Indole-3-Carbinol (I3C)
Find Indole-3-Carbinol (I3C) on iHerb →The evidence for Indole-3-Carbinol (I3C)
Graded by what exists behind each claim.
✅ Clinically validated
- Trials show shifts in estrogen metabolism toward the 2-hydroxy pathway and away from 16-alpha-hydroxy.
- Small trials report regression of cervical intraepithelial neoplasia and recurrent respiratory papillomatosis.
- Whether the estrogen-ratio shift translates to any clinical outcome remains unproven — that is the honest limit of this compound.
📊 Correlative data
- High cruciferous vegetable intake is associated with lower hormone-sensitive cancer risk in cohorts.
🧪 Theoretical / extrapolated benefits
- Induces CYP1A1/1A2, shifting estrogen hydroxylation. Also an aryl hydrocarbon receptor ligand, which is where the mixed preclinical signal comes from.
How to read these tiers: they say how much human evidence exists, not how well something works — and ✗ flags harm, never a disappointing trial. How the evidence tiers work →
What Indole-3-Carbinol (I3C) actually does
This is the clearest case of the conversion problem in the whole catalog, and the vendor's own card already half admits it: the parent compound becomes something else in the stomach. Indole-3-carbinol is not stable at pH 2. It self-condenses within minutes into a mixture whose major member is 3,3'-diindolylmethane, alongside the linear trimer, the cyclic trimer, and indolo[3,2-b]carbazole. The molecule that leaves the stomach is not the molecule that entered it, and the product mixture depends on gastric pH, on residence time and therefore on whether the capsule was taken with food.
One of those products is not a mild nutraceutical. Indolo[3,2-b]carbazole is among the most potent known agonists of the aryl hydrocarbon receptor, the same ligand-activated transcription factor that dioxin binds. Activating it induces CYP1A1, CYP1A2 and CYP1B1 through the xenobiotic response element. That is the real mechanism behind the estrogen-metabolism marketing: induced CYP1A2 shifts estradiol hydroxylation toward the 2-hydroxy pathway and away from the 16-alpha-hydroxy pathway, which is what the 2-hydroxyestrone to 16-alpha-hydroxyestrone ratio is measuring.
The upstream chemistry explains why this is a cruciferous story. Broccoli and its relatives store glucobrassicin, a glucosinolate. Myrosinase, released when the plant tissue is crushed, hydrolyzes it to an unstable isothiocyanate that loses thiocyanate and gives indole-3-carbinol. So there are 2 conversions in series before anything reaches a receptor: plant enzyme first, stomach acid second, and the review that traces indoles from glucobrassicin to their chemopreventive products follows exactly that path Williams 2021.
The post-ingestion step has now been characterized directly. Work on the conversion of dietary indoles into their active forms after ingestion is the load-bearing citation for this page Lin 2022, and the cell-signaling review that pairs indole-3-carbinol with its condensation product treats the 2 as a parent and a product rather than as alternatives Reyes-Hernández 2023.
Then the product is itself metabolized, which most pages stop before reaching. After oral dosing in humans, 3,3'-diindolylmethane undergoes substantial metabolism rather than circulating unchanged Vermillion Maier 2021. So the chain is glucosinolate, then plant enzyme, then acid condensation, then hepatic oxidation and conjugation - 4 transformations between the vegetable and the receptor, and the label describes only the first molecule in the sequence.
Which is why the practitioner shift to the downstream compound is a chemistry decision, not a branding one. Dosing the condensation product directly removes 1 uncontrolled step and, with it, the production of the high-potency aryl hydrocarbon receptor agonist that only forms under acid. Both compounds still activate the receptor; only 1 of them does so through a mixture nobody has quantified in a living stomach.
Cell, rodent, human — and where it stops
The human end of this is better than for most botanicals, and every human study is of the product rather than the parent.
In people, with a hormone endpoint. The effect of 3,3'-diindolylmethane on estradiol and on estrogen metabolism was measured in postmenopausal women using a transdermal estradiol patch Newman 2025. A fixed exogenous estradiol input with a measured metabolite output is close to a clean experiment, and it is the design this claim needed.
In people, with a carcinogen endpoint. Benzo[a]pyrene toxicokinetics were measured in humans after supplementation with 3,3'-diindolylmethane or with Brussels sprouts Vermillion Maier 2023. That is a direct test of the induced-enzyme mechanism, using a labeled probe, in living volunteers.
In people, with a pharmacokinetic endpoint. Oral dosing in humans shows extensive metabolism of the compound Vermillion Maier 2021, which is what sets the ceiling on how much reaches tissue.
Here is the obstacle, and it is specific rather than generic. None of those studies dosed indole-3-carbinol. They dosed the condensation product. A page that cites them under the parent compound's name is quietly assuming that a fixed, known fraction of a capsule converts, and the acid-condensation literature says the yield is a mixture rather than a fraction Lin 2022. The human evidence belongs to the downstream molecule.
The rodent cancer literature adds a second obstacle in the opposite direction. In some animal models, giving the parent compound AFTER a carcinogen promoted tumors rather than preventing them, which is the origin of the caution on the product card. That biphasic behavior is a property of an aryl hydrocarbon receptor agonist and of the induced enzymes, which can activate a procarcinogen as readily as they clear one Williams 2021. Timing relative to exposure decides the sign of the effect, and no human study has tested that.
Indole-3-Carbinol (I3C) — which form, and does it matter
The form question here is the whole page: parent compound or condensation product. They are sold side by side at similar prices and they are not versions of one another. One is a precursor that generates an uncontrolled mixture under acid; the other is the defined major member of that mixture.
Doses are not comparable across the 2 and nobody says so. A typical parent dose is 200 to 400 mg daily. The condensation reaction consumes 2 molecules of the parent per molecule of product and does not go to completion, so the delivered quantity of the studied compound is a fraction of the label figure and the fraction is not fixed Lin 2022. Comparing 400 mg of the parent with 200 mg of the product as though they were the same exposure is arithmetic nobody has justified.
Bioavailability is the second half of the form question. The condensation product is poorly water soluble, so it is often sold in an absorption-enhanced formulation - typically a microencapsulated or phospholipid-complexed material - and those preparations reach several times the plasma concentration of the crystalline powder at the same milligram figure. Given how extensively the compound is metabolized after absorption Vermillion Maier 2021, the delivery form is doing at least as much work as the number on the front of the bottle.
Food changes the reaction, so it changes the dose. The parent compound converts under acid; a capsule taken with a large meal meets a buffered stomach and a longer residence time, and a capsule taken fasting meets pH 1.5 to 2. That is a real variable, it is unmeasured, and it belongs on the label rather than in a footnote.
And the vegetable is a third form with a different problem. Cooking denatures myrosinase, so boiled broccoli delivers glucobrassicin that the plant can no longer hydrolyze and hands the job to the gut microbiota, whose capacity for it varies enormously between people Williams 2021. Raw cruciferous vegetables and a capsule are not interchangeable, in either direction.
What would have to be true, and how you would know it was not
1. The estrogen-metabolism prediction, at 8 to 12 weeks. A urinary 2-hydroxyestrone to 16-alpha-hydroxyestrone ratio at baseline and at 12 weeks. Prediction: the ratio rises, because the mechanism is induction of the enzyme that makes the 2-hydroxy metabolite, and that is the pathway measured in the transdermal-estradiol study Newman 2025. If the ratio does not move, the capsule did not convert or did not absorb.
2. The prediction that exposes the drug interaction, and it is the one nobody makes. CYP1A2 induction accelerates clearance of caffeine, theophylline, tizanidine, olanzapine and clozapine. Prediction: subjective caffeine tolerance rises within 2 to 3 weeks of starting, because the same enzyme handles it. That is a crude read-out and it is free, and for anyone on an affected medication it is a prompt to talk to the prescriber rather than to adjust anything.
3. The thyroid prediction, which runs against the product. Thyroid-stimulating hormone, free thyroxine and free triiodothyronine at baseline and 12 weeks. Prediction: no change in an iodine-replete person, because the goitrogenic concern for cruciferous compounds belongs to thiocyanate at intakes far above a capsule. A rise in thyroid-stimulating hormone would be a genuine and reportable finding.
4. Predict the liver panel does not move and check anyway. Alanine aminotransferase and aspartate aminotransferase at baseline and 12 weeks. A compound that induces 3 cytochrome isoforms is changing hepatic workload, and a baseline is what makes a later number interpretable Reyes-Hernández 2023.
5. The experiment that would settle parent against product for one person. 8 weeks on 400 mg of the parent, a 4-week washout, then 8 weeks on an equivalent labeled dose of the condensation product, with the same urinary estrogen metabolite ratio measured at the end of each block. Prediction: the product arm moves the ratio further per milligram, because it skips a reaction with an unmeasured yield Lin 2022. Nobody has published this comparison.
What nobody has tested yet
Nobody has measured the conversion yield in a living human stomach. The chemistry is known and the products are known Lin 2022. What fraction of a 400 mg capsule becomes the major product, what fraction becomes the trimer, and what fraction becomes the high-potency aryl hydrocarbon receptor agonist, in a real person, fed or fasted, has not been reported.
Nobody has run the parent compound in a human trial with a clinical endpoint. The human studies are of the product Newman 2025 Vermillion Maier 2023 Vermillion Maier 2021. The parent's human dataset is essentially tolerability and short-term biomarker work.
Nobody has resolved the promotion signal. The animal finding that post-initiation dosing promoted tumors in some models has never been followed by a study designed to test whether it applies to humans at supplemental doses Williams 2021. That is an unanswered question rather than a demonstrated risk, and it is why the product card recommends the downstream compound.
And nobody has quantified the drug interaction. A caffeine or midazolam probe study before and after 4 weeks of dosing would put a number on CYP1A2 induction. It has not been done, so the interaction is stated as a direction with no magnitude Reyes-Hernández 2023.
Indole-3-Carbinol (I3C) — its own safety story, not its category's
The specific risk here is enzyme induction, and it is a risk to other medicines rather than to the liver. Induction of CYP1A2 lowers plasma concentrations of drugs cleared by it. For clozapine, olanzapine, theophylline and tizanidine that means loss of effect or a changed dose requirement, and neither is something to discover by accident. This belongs in a conversation with the prescriber before starting.
The gastrointestinal complaints are dose-related and unremarkable. Nausea and loose stool at the top of the range, resolving on splitting the dose. A harmless and often alarming effect of the downstream compound is a change in urine color toward brown-orange, which is a chromophore and not a sign of injury.
The population where this is not a casual purchase is people with a hormone-sensitive cancer history. A compound that shifts estrogen metabolism Newman 2025 is an endocrine intervention, and an endocrine intervention in that population is an oncologist's decision. This page does not diagnose or treat anything, and it is not an argument for or against any therapy.
The animal promotion finding is the reason the parent compound is the less preferred form. It has not been shown in humans and it has not been excluded, and the honest position is to say both halves Williams 2021. Somebody with a known carcinogen exposure history has a reason to prefer the defined compound.
And 2 groups with no data at all. Pregnancy and breastfeeding, where a compound that activates the same receptor as dioxin and induces fetal-relevant enzymes has no controlled exposure data; and children, for the same reason. None of these statements has been evaluated by the Food and Drug Administration.
Sources read for this page
- Lin LP. Post-ingestion conversion of dietary indoles into anticancer agents. Natl Sci Rev 2022 · PMID 35505660
- Vermillion Maier ML. 3,3'-Diindolylmethane Exhibits Significant Metabolism after Oral Dosing in Humans. Drug Metab Dispos 2021 · PMID 34035125
- Vermillion Maier ML. Benzo[a]pyrene toxicokinetics in humans following dietary supplementation with 3,3'-Diindolylmethane (DIM) or Brussels sprouts. Toxicol Appl Pharmacol 2023 · PMID 36642108
- Newman MS. The impact of 3,3'-diindolylmethane on estradiol and estrogen metabolism in postmenopausal women using a transdermal estradiol patch. Menopause 2025 · PMID 40298801
- Williams DE. Indoles Derived From Glucobrassicin: Cancer Chemoprevention by Indole-3-Carbinol and 3,3'-Diindolylmethane. Front Nutr 2021 · PMID 34660663
- Reyes-Hernández OD. 3,3'-Diindolylmethane and indole-3-carbinol: potential therapeutic molecules for cancer chemoprevention and treatment via regulating cellular signaling pathways. Cancer Cell Int 2023 · PMID 37633886
How you would know if it worked
What this compound is documented to shift is a ratio between two estrogen metabolites, 2-hydroxy against 16-alpha-hydroxy, and that ratio is measured in urine. It is not on this menu and it is not what a blood draw will tell you, so be clear about which question you are answering. The blood pair answers the cruder one: whether total estrogen exposure changed at all, six to eight weeks in. Worth knowing, because the metabolite shift can happen with the totals unmoved — and because the conversion to DIM in stomach acid is variable enough that two people on the same dose are not necessarily running the same experiment, which is the argument for taking the stable end-product instead. Whether either number predicts an outcome anyone cares about is unproven. That is the honest limit here.
- Estradiol, Sensitive (LC/MS-MS) Retest: 6–8 weeks after any TRT or AI change.
- Estrogens, Total Retest: With estradiol.
Draw before you start, not after. A result with nothing to compare it to answers nothing.
Indole-3-Carbinol (I3C) — safety & side effects
- The precursor DIM is made from, and less predictable because that conversion happens in stomach acid and varies with acid-suppressing medication.
- Same CYP1A2 induction and estrogen-metabolism shift as DIM. At high doses and long duration, animal data are mixed rather than uniformly reassuring — DIM is the better-characterized choice if you want this pathway.
The same on every page it applies to. Read it here; it is not repeated research.
- Avoid if you have or have had a hormone-sensitive cancer (breast, ovarian, uterine, prostate) without oncology input. The mechanism that makes it useful is the mechanism that makes it a question in that setting.
Not medical advice. If you take prescription medication or have a diagnosed condition, check this against it with a pharmacist or doctor — pharmacists are underused and free.
- When to take it, and what to take it with
- Which form actually absorbs
- Who it's worth it for
- Coach Cam's stacks and notes
- Fasted or with food, and when in the day
- Morning or night, and why that window
- Around training, or deliberately away from it
- What it must not share a window with
Everything above is free and stays free. Skool is where it becomes a plan — Indole-3-Carbinol (I3C) in an order, with the rest of what you're running.
Unlock in Skool — $10/mo →Bloodwork to run alongside Indole-3-Carbinol (I3C)
Baseline first, then again at 8–12 weeks.
| Marker | What it’s watching for |
|---|---|
| TSH (Thyroid-Stimulating Hormone) | Thyroid sits upstream of most things labeled 'hormonal' |
| Free T4 (Thyroxine) | Distinguishes a real thyroid problem from a borderline TSH |
| Total Testosterone | The baseline, if any of this is aimed at androgens |
| Vitamin D (25-Hydroxy) | Behaves like a hormone and is commonly low |
The Basics — Start Here panel covers these in one order — 4 markers, $32.40 with the discount applied.
Check results you already have → · All 103 markers A–Z
Indole-3-Carbinol (I3C) — frequently asked questions
What is Indole-3-Carbinol (I3C)?
The parent compound that becomes DIM in the stomach. Choosing between the two is not just a branding question — the conversion is messy.
What is the suggested dose of Indole-3-Carbinol (I3C)?
200–400 mg daily with food. This is a general reference for education only — statements have not been evaluated by the FDA and this is not medical advice.
Where can I find Indole-3-Carbinol (I3C) dosing and the full breakdown?
The suggested dose and the full evidence — clinical, correlative and theoretical — are on this page. What's inside Skool is when to take it, which form actually absorbs, the brand worth buying and Coach Cam's stacks.
Where can I buy Indole-3-Carbinol (I3C)?
Coach Cam sources Indole-3-Carbinol (I3C) from vetted, top-rated brands on iHerb — use the buy link on this page.
Indole-3-Carbinol (I3C) inside a finished plan
One arm of 1 Protocol Blueprint, free to read in full.
What Indole-3-Carbinol (I3C) is used for
Indole-3-Carbinol (I3C) appears under 2 goals in the goal router.
Related Hormonal & Wellness supplements
Where this goes next
Indole-3-Carbinol (I3C) is the aromatase arm of this plan. The page above is the free breakdown of one compound; the plan it belongs to — the dosing, the order to correct things in, the week-by-week schedule and what to retest — is a lesson inside Skool.